Novo Nordisk unveils new drug to fight obesity, says 13% effective
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
Drugs
Health
Pharma